<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-5633</journal-id>
<journal-title><![CDATA[Revista Colombiana de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Colomb. Cardiol.]]></abbrev-journal-title>
<issn>0120-5633</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Colombiana de Cardiologia. Oficina de Publicaciones]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-56332024000100012</article-id>
<article-id pub-id-type="doi">10.24875/rccar.22000008</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Frecuencia y distribución geográfica del uso de sacubitril/valsartán en Colombia entre los años 2019 y 2020]]></article-title>
<article-title xml:lang="en"><![CDATA[Frequency and geographical distribution of the use of sacubitril/valsartan in Colombia between 2019 and 2020]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Herrera-Leaño]]></surname>
<given-names><![CDATA[Nancy]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Barahona-Correa]]></surname>
<given-names><![CDATA[Julián E.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Muñoz-Velandia]]></surname>
<given-names><![CDATA[Oscar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fernández-Ávila]]></surname>
<given-names><![CDATA[Daniel G.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[Ángel A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Pontificia Universidad Javeriana Departamento de Medicina Interna ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Universitario San Ignacio Departamento de Medicina Interna ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Universitario San Ignacio Unidad de Reumatología ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Hospital Universitario San Ignacio Unidad de Cardiología ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2024</year>
</pub-date>
<volume>31</volume>
<numero>1</numero>
<fpage>12</fpage>
<lpage>18</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-56332024000100012&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-56332024000100012&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-56332024000100012&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: La adherencia al tratamiento de la falla cardiaca en la vida real es subóptima. Se desconoce la adherencia a las recomendaciones del uso de sacubitril/valsartán en Colombia.  Objetivo: Evaluar la frecuencia de uso, la distribución geográfica y las características demográficas de los pacientes a quienes se les formuló sacubitril/valsartán en 2019-2020, utilizando los datos del Sistema Integrado de Información de Protección Social (SISPRO).  Materiales y método: Estudio descriptivo de corte transversal, en el que se extrajo la información relativa a la distribución de la prescripción del medicamento por departamento, género, quinquenio de edad y los códigos CIE-10 con los cuales se indicó.  Resultados: Entre los años 2019 y 2020, se prescribieron 23.026 pacientes con sacubitril/valsartán en Colombia, de los cuales el 63.86% fueron hombres. El 92% de las prescripciones se hicieron a pacientes mayores de 50 años. Las regiones del país con mayor frecuencia de prescripción fueron Bogotá, Sucre y Santander.  Conclusiones: Con base en la prevalencia estimada de falla cardiaca (2 a 3%), la frecuencia de formulación de sacubitril/valsartán en Colombia es menor a la esperada. Las regiones rurales del país son las que presentan el menor uso, lo que sugiere barreras de acceso que deben ser exploradas.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: Real-life adherence to the management of heart failure is suboptimal. Adherence to the recommendations for the use of sacubitril/valsartan in Colombia is unknown.  Objective: To assess the frequency of use, geographic distribution, and demographic characteristics of patients who were prescribed sacubitril/valsartan in 2019-2020, using data from the &#8220;Sistema Integrado de Información de Protección Social&#8221; (SISPRO).  Materials and method: This is a descriptive cross-sectional study. Information was extracted on the prescription distribution by department, gender, five-year age groups and the ICD-10 codes with which the medication was prescribed.  Results: Between 2019 and 2020, 23,026 patients in Colombia were prescribed sacubitril/valsartan; 63.86% of the patients were men. Ninety-two percent of the prescriptions were for patients over the age of 50. The regions of the country with the highest prescription frequency were Bogotá, Sucre and Santander.  Conclusions: Taking into account the estimated prevalence of heart failure (2-3%), the frequency with which sacubitril/valsartan is prescribed in Colombia is lower than expected. The rural regions of the country have the lowest use, which suggests access barriers that should be explored.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Sacubitril/valsartán]]></kwd>
<kwd lng="es"><![CDATA[Falla cardiaca]]></kwd>
<kwd lng="es"><![CDATA[Colombia]]></kwd>
<kwd lng="en"><![CDATA[Sacubitril/valsartan]]></kwd>
<kwd lng="en"><![CDATA[Heart failure]]></kwd>
<kwd lng="en"><![CDATA[Colombia]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>Institute for Health Metric and Evaluation (IHME)</collab>
<source><![CDATA[Global burden of Disease Study 2019]]></source>
<year>2019</year>
<publisher-name><![CDATA[University of Washington]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Milinkovi&#263;]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Polovina]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Seferovi&#263;]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Age old problem:heart failure treatment in elderly]]></article-title>
<source><![CDATA[Eur J Prev Cardiol]]></source>
<year>2019</year>
<volume>26</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>1396-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Capítulo 2. Introducción, epidemiología de la falla cardiaca e historia de las clínicas de falla cardiaca en Colombia]]></article-title>
<source><![CDATA[Rev Colomb Cardiol]]></source>
<year>2016</year>
<volume>23</volume>
<page-range>6-12</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McMurray]]></surname>
<given-names><![CDATA[JJV]]></given-names>
</name>
<name>
<surname><![CDATA[Packer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Desai]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Gong]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lefkowitz]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Rizkala]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Angiotensin&#8211;Neprilysin Inhibition Versus Enalapril In Heart Failure]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2014</year>
<volume>371</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>993-1004</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Greene]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Butler]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Albert]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
<name>
<surname><![CDATA[DeVore]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[PP]]></given-names>
</name>
<name>
<surname><![CDATA[Duffy]]></surname>
<given-names><![CDATA[CI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medical therapy for heart failure with reduced ejection fraction]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2018</year>
<volume>72</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>351-66</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chaves]]></surname>
<given-names><![CDATA[Santiago WG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cumplimiento de guías en pacientes hospitalizados con falla cardiáca ¿Cómo estamos?]]></article-title>
<source><![CDATA[Acta Médica Colomb]]></source>
<year>2014</year>
<volume>39</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>40-5</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<collab>Ministerio de Salud y Protección Social</collab>
<source><![CDATA[Cifras de aseguramiento en salud con corte noviembre de 2021]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández-Ávila]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Bernal-Macías]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rincón-Riaño]]></surname>
<given-names><![CDATA[DN]]></given-names>
</name>
<name>
<surname><![CDATA[Gutiérrez]]></surname>
<given-names><![CDATA[Dávila JM]]></given-names>
</name>
<name>
<surname><![CDATA[Rosselli]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of systemic lupus erythematosus in Colombia:data from the National Health Registry 2012&#8211;2016]]></article-title>
<source><![CDATA[Lupus]]></source>
<year>2019</year>
<volume>28</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1273-8</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández-Ávila]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Rincón-Riaño]]></surname>
<given-names><![CDATA[DN]]></given-names>
</name>
<name>
<surname><![CDATA[Bernal-Macías]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gutiérrez]]></surname>
<given-names><![CDATA[Dávila JM]]></given-names>
</name>
<name>
<surname><![CDATA[Rosselli]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalencia y características demográficas del síndrome de Sjögren en Colombia, según información del Sistema Integral de Información de la Protección Social]]></article-title>
<source><![CDATA[Reumatol Clínica]]></source>
<year>2020</year>
<volume>16</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>286-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández-Ávila]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Bernal-Macías]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rincón-Riaño]]></surname>
<given-names><![CDATA[DN]]></given-names>
</name>
<name>
<surname><![CDATA[Gutiérrez]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Rosselli]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of polymyalgia rheumatica in Colombia:data from the National Health Registry 2012&#8211;2016]]></article-title>
<source><![CDATA[Rheumatol Int]]></source>
<year>2019</year>
<volume>39</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1631-5</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McDonagh]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Metra]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Adamo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gardner]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Baumbach]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Böhm]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2021</year>
<volume>42</volume>
<numero>36</numero>
<issue>36</issue>
<page-range>3599-726</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Luo]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Fonarow]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
<name>
<surname><![CDATA[Lippmann]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Mi]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Heidenreich]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Yancy]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early adoption of sacubitril/valsartan for patients with heart failure with reduced ejection fraction]]></article-title>
<source><![CDATA[JACC Hear Fail]]></source>
<year>2017</year>
<volume>5</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>305-9</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McMurray]]></surname>
<given-names><![CDATA[JJV]]></given-names>
</name>
<name>
<surname><![CDATA[Solomon]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Inzucchi]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Køber]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kosiborod]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dapagliflozin in patients with heart failure and reduced ejection fraction]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2019</year>
<volume>381</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>1995-2008</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Packer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Anker]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Butler]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Filippatos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Pocock]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Empagliflozin in patients with heart failure, reduced ejection fraction, and volume overload]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2021</year>
<volume>77</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1381-92</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Armstrong]]></surname>
<given-names><![CDATA[PW]]></given-names>
</name>
<name>
<surname><![CDATA[Pieske]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Anstrom]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ezekowitz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hernandez]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Butler]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vericiguat in patients with heart failure and reduced ejection fraction]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2020</year>
<volume>382</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>1883-93</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Teerlink]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Diaz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Felker]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[McMurray]]></surname>
<given-names><![CDATA[JJV]]></given-names>
</name>
<name>
<surname><![CDATA[Metra]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Solomon]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2021</year>
<volume>384</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>105-16</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruiz]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Los recursos humanos de la salud en Colombia]]></article-title>
<source><![CDATA[Balance, competencias y prospectiva [Internet]]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Campaz]]></surname>
<given-names><![CDATA[Payan N]]></given-names>
</name>
</person-group>
<source><![CDATA[Barreras de acceso al servicio de salud en el contexto colombiano a partir de la promulgación del derecho a la salud en la legislación colombiana [Internet]]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parra-Medina]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Barahona-Correa]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chaves]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Páyan-Gomez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ramirez-Clavijo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fenández-Ávila]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence and demographic characteristics of prostate cancer patients in Colombia:data from the National Health Registry from 2015 to 2019]]></article-title>
<source><![CDATA[Rev Urol Colomb/Colomb Urol J]]></source>
<year>2021</year>
<volume>30</volume>
<numero>03</numero>
<issue>03</issue>
<page-range>e204-9</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lam]]></surname>
<given-names><![CDATA[CSP]]></given-names>
</name>
<name>
<surname><![CDATA[Arnott]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Beale]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Chandramouli]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hilfiker-Kleiner]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kaye]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sex differences in heart failure]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2019</year>
<volume>40</volume>
<numero>47</numero>
<issue>47</issue>
<page-range>3859-3868c</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roger]]></surname>
<given-names><![CDATA[VL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of heart failure]]></article-title>
<source><![CDATA[Circ Res]]></source>
<year>2021</year>
<volume>128</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1421-34</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Savarese]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Lund]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global Public health burden of heart failure]]></article-title>
<source><![CDATA[Card Fail Rev]]></source>
<year>2017</year>
<volume>03</volume>
<numero>01</numero>
<issue>01</issue>
<page-range>7</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verhestraeten]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Heggermont]]></surname>
<given-names><![CDATA[WA]]></given-names>
</name>
<name>
<surname><![CDATA[Maris]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical inertia in the treatment of heart failure:a major issue to tackle]]></article-title>
<source><![CDATA[Heart Fail Rev]]></source>
<year>2021</year>
<volume>26</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1359-70</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Erhardt]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Komajda]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hobbs]]></surname>
<given-names><![CDATA[FDR]]></given-names>
</name>
<name>
<surname><![CDATA[Soler-Soler]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiologists'awareness and perceptions of guidelines for chronic heart failure. The ADDress your Heart survey]]></article-title>
<source><![CDATA[Eur J Heart Fail]]></source>
<year>2008</year>
<volume>10</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1020-5</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calvin]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Shanbhag]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Avery]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Kane]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Richardson]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Powell]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adherence to evidence-based guidelines for heart failure in physicians and their patients:lessons from the Heart Failure Adherence Retention Trial (HART)]]></article-title>
<source><![CDATA[Congest Hear Fail]]></source>
<year>2012</year>
<volume>18</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>73-8</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thygesen]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Ersbøll]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[When the entire population is the sample:strengths and limitations in register-based epidemiology]]></article-title>
<source><![CDATA[Eur J Epidemiol]]></source>
<year>2014</year>
<volume>29</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>551-8</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="">
<source><![CDATA[Ministerio de Salud y Protección Social. Plan-obligatorio-de-salud-pos [Internet]]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<collab>Delegatura para la Protección de la Competencia</collab>
<article-title xml:lang=""><![CDATA[Estudio del sector farmacéutico en Colombia]]></article-title>
<source><![CDATA[Estudios de mercado [Internet]]]></source>
<year>2020</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
